{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:20:39Z","timestamp":1787239239627,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Taiwan Ministry of Health and Welfare Clinical Trial Center","award":["MOHW109-TDU-B-212-114004"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114004"]}]},{"name":"Ministry of Science and Technology Clinical Trial Consortium for Stroke","award":["MOST 108-2321-B-039-003-"],"award-info":[{"award-number":["MOST 108-2321-B-039-003-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12072-020-10122-1","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T06:03:29Z","timestamp":1610258609000},"page":"179-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan"],"prefix":"10.1007","volume":"15","author":[{"given":"Fu-Shun","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei-Tung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"key":"10122_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13115","volume":"36","author":"L Elkrief","year":"2016","unstructured":"Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936\u201348.","journal-title":"Liver Int"},{"key":"10122_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992\u20131019.","journal-title":"Endocr Rev"},{"key":"10122_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/ijcp.12361","volume":"68","author":"S Brunton","year":"2014","unstructured":"Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68:557\u201367.","journal-title":"Int J Clin Pract"},{"key":"10122_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.5754\/hge11263","volume":"58","author":"T Iwasaki","year":"2011","unstructured":"Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011;58:2103\u20135.","journal-title":"Hepatogastroenterology"},{"key":"10122_CR5","first-page":"240","volume":"75","author":"Y Yilmaz","year":"2012","unstructured":"Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75:240\u20134.","journal-title":"Acta Gastroenterol Belg"},{"key":"10122_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187\u2013215.","journal-title":"Endocr Rev"},{"key":"10122_CR7","doi-asserted-by":"publisher","first-page":"E773","DOI":"10.1152\/ajpendo.00507.2003","volume":"286","author":"KH Ding","year":"2004","unstructured":"Ding KH, Zhong Q, Xu J, Isales CM. Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs portal vein endothelial cells. Am J Physiol Endocrinol Metab. 2004;286:E773\u20139.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10122_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","volume":"22","author":"M Cheng","year":"2003","unstructured":"Cheng M. Taiwan\u2019s new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61\u201376.","journal-title":"Health Aff (Millwood)"},{"key":"10122_CR9","first-page":"157","volume":"104","author":"CC Lin","year":"2005","unstructured":"Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157\u201363.","journal-title":"J Formos Med Assoc"},{"key":"10122_CR10","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182688d2f","volume":"47","author":"MS Nehra","year":"2013","unstructured":"Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013;47:e50\u20134.","journal-title":"J Clin Gastroenterol"},{"key":"10122_CR11","doi-asserted-by":"publisher","first-page":"318627","DOI":"10.1155\/2012\/318627","volume":"2012","author":"AN Mukerji","year":"2012","unstructured":"Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol. 2012;2012:318627.","journal-title":"Int J Hepatol"},{"key":"10122_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11606-007-0310-5","volume":"22","author":"P Meduru","year":"2007","unstructured":"Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22:408\u201318.","journal-title":"J Gen Intern Med"},{"key":"10122_CR13","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, Everson-Stewart S, Kinder L, Oliver M, Boyko EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and health care utilization. Am J Manag Care. 2008;14:15\u201323.","journal-title":"Am J Manag Care"},{"issue":"3","key":"10122_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12072-015-9637-x","volume":"9","author":"X Wang","year":"2015","unstructured":"Wang X, Sarin SK, Ning Q. Definition of ACLF and inclusion criteria for extra-hepatic organ failure. Hepatol Int. 2015;9(3):360\u20135.","journal-title":"Hepatol Int"},{"key":"10122_CR15","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265\u201381.","journal-title":"Stat Med"},{"key":"10122_CR16","volume-title":"Risk adjustment for measuring healthcare outcomes","author":"LI Iezzoni","year":"1997","unstructured":"Iezzoni LI. Risk adjustment for measuring healthcare outcomes. Chicago: Health Administration Press; 1997."},{"key":"10122_CR17","doi-asserted-by":"crossref","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1736\u20131788","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"10122_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1478-3231.2011.02517.x","volume":"32","author":"KM Fleming","year":"2012","unstructured":"Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 2012;32:79\u201384.","journal-title":"Liver Int"},{"key":"10122_CR19","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","volume":"122","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018;122:1439\u201359.","journal-title":"Circ Res"},{"key":"10122_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"10122_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S2213-8587(20)30112-1","volume":"8","author":"A Gouverneur","year":"2020","unstructured":"Gouverneur A, Lair A, Arnaud M, Begaud B, Raschi E, Pariente A, Salvo F. DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database. Lancet Diabetes Endocrinol. 2020;8:365\u20137.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10122_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/09537104.2012.721907","volume":"23","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012;23:565\u201370.","journal-title":"Platelets"},{"key":"10122_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1463-1326.2010.01214.x","volume":"12","author":"M Ligueros-Saylan","year":"2010","unstructured":"Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495\u2013509.","journal-title":"Diabetes Obes Metab"},{"key":"10122_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s40064-015-1135-z","volume":"4","author":"M Asakawa","year":"2015","unstructured":"Asakawa M, Mitsui H, Akihisa M, Sekine T, Niitsu Y, Kobayashi A, Hashimoto N, Kawamura M, Ogawa Y. Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury. Springerplus. 2015;4:346.","journal-title":"Springerplus"},{"key":"10122_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2005.10.004","volume":"44","author":"DA Langer","year":"2006","unstructured":"Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006;44:209\u201316.","journal-title":"J Hepatol"},{"key":"10122_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1185\/03007995.2011.602964","volume":"27","author":"M Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27:57\u201364.","journal-title":"Curr Med Res Opin"},{"key":"10122_CR27","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","volume":"19","author":"M Itou","year":"2013","unstructured":"Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013;19:2298\u2013306.","journal-title":"World J Gastroenterol"},{"key":"10122_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2957\/kanzo.53.164","volume":"53","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S, Tokuhara T, Nishikawa M, Nishizawa S, Nishioka T, Nozawa A, Takahashi A, Watanabe Y, Wada R, Wakasa K, et al. Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: possibly responsible for immune system. Kanzo. 2012;53:164\u20137.","journal-title":"Kanzo"},{"key":"10122_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000343458","volume":"87","author":"F Gundling","year":"2013","unstructured":"Gundling F, Seidl H, Strassen I, Haller B, Siegmund T, Umgelter A, Pehl C, Schepp W, Schumm-Draeger PM. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion. 2013;87:75\u201384.","journal-title":"Digestion"},{"key":"10122_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5811\/westjem.2018.7.37893","volume":"19","author":"MF Harrison","year":"2018","unstructured":"Harrison MF. The misunderstood coagulopathy of liver disease: a review for the acute setting. West J Emerg Med. 2018;19:863\u201371.","journal-title":"West J Emerg Med"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10122-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:48:13Z","timestamp":1613681293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10122-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10122"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10122-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,10]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Research Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115). All information identifying care providers or patients was encrypted, and we were permitted to waive informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"To protect individual privacy, all patient or caregiver data were scrambled before being released. This study was approved by the Research Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115-CR-4) and was exempted from informed consent requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}